Technical Analysis for STRO - Sutro Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | -2.42% | |
| Up 4 Days in a Row | Strength | -2.42% | |
| 20 DMA Support | Bullish | -0.59% | |
| 50 DMA Support | Bullish | -0.59% | |
| Up 3 Days in a Row | Strength | -0.59% |
| Alert | Time |
|---|---|
| 50 DMA Support | 2 days ago |
| 20 DMA Support | 2 days ago |
| Down 3% | 2 days ago |
| Fell Below 20 DMA | 2 days ago |
| Outside Day | 2 days ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
Sutro Biopharma, Inc. Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunology Antibodies Cancer Treatment Drug Discovery Lymphoma Antineoplastic Drugs Multiple Myeloma Autoimmune Disorders Immune Disorders Endometrial Cancer Immunogen Therapeutics For Cancer Hodgkin Lymphoma Milatuzumab Non Hodgkin Lymphoma Ovarian And Endometrial Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.13 |
| 52 Week Low | 2.005 |
| Average Volume | 1,033,984 |
| 200-Day Moving Average | 3.93 |
| 50-Day Moving Average | 4.16 |
| 20-Day Moving Average | 4.20 |
| 10-Day Moving Average | 4.27 |
| Average True Range | 0.34 |
| RSI (14) | 51.46 |
| ADX | 25.55 |
| +DI | 28.67 |
| -DI | 17.64 |
| Chandelier Exit (Long, 3 ATRs) | 4.06 |
| Chandelier Exit (Short, 3 ATRs) | 4.41 |
| Upper Bollinger Bands | 4.60 |
| Lower Bollinger Band | 3.81 |
| Percent B (%b) | 0.53 |
| BandWidth | 18.86 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.05 |
| MACD Histogram | 0.0069 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.72 | ||||
| Resistance 3 (R3) | 4.75 | 4.61 | 4.64 | ||
| Resistance 2 (R2) | 4.61 | 4.48 | 4.59 | 4.61 | |
| Resistance 1 (R1) | 4.42 | 4.40 | 4.35 | 4.39 | 4.58 |
| Pivot Point | 4.28 | 4.28 | 4.24 | 4.26 | 4.28 |
| Support 1 (S1) | 4.09 | 4.15 | 4.02 | 4.06 | 3.87 |
| Support 2 (S2) | 3.95 | 4.07 | 3.94 | 3.84 | |
| Support 3 (S3) | 3.76 | 3.95 | 3.81 | ||
| Support 4 (S4) | 3.73 |
